Alnylam Pharmaceuticals Receives $2 Billion Funding from Blackstone
Alnylam Pharmaceuticals (ALNY) announced that Blackstone Group (BX) has decided to invest up to $2 billion through a combination of debt and equity. The funding will impart the much-needed liquidity to the company and will help in bringing more products to the market. As part of the deal, Blackstone will acquire up to 50 percent of the future royalties of inclisiran through its Blackstone Life Sciences unit. The drug is designed to treat high levels of cholesterol.
Blackstone Life Sciences was launched by the private